₹1057.3
-15.6 (-1.45%) - 15 Jul 2025 03:23 PMGlenmark Life Sciences Limited is a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system disease (CNS), pain management and diabetes. It also manufacture and sell APIs for gastro-intestinal disorders, anti-infectives and other therapeutic areas. Its API portfolio comprises specialized and profitable products, including niche and technically complex molecules, which reflects its capability to branch into other high value products. It has strong market share in select specialized APIs such as Telmisartan (anti-hypertensive), Atovaquone (anti-parasitic), Perindopril (anti-hypertensive), Teneligliptin (diabetes), Zonisamide (CNS) and Adapalene (dermatology). The company currently operates four multi-purpose manufacturing facilities which are situated on leasehold properties located at Ankleshwar and Dahej in the state of Gujarat, India, and Mohol and Kurkumbh in the state of Maharashtra, India.
Industry - Pharmaceuticals & Drugs
* Please refer to the Standalone data if Consolidated financial data for the company is not available.
Copyright © 2025 All rights reserved with INVESMATE INSIGHTS PRIVATE LIMITED
| All logos and Trademarks registered with their respective owners.
